> Roche has unveiled new data that demonstrates a significantly improved response for its HIV treatment Fuzeon. Report
> Palatin Technologies has pulled an infection diagnosing agent from the market following the deaths of two people. Release
> Acambis has become the first drug developer to begin a Phase II trial of a vaccine designed to prevent West Nile disease. Release
> New research indicates that people taking heartburn medications like Prilosec, Prevacid and Nexium are more likely to get diarrhea caused by the bacteria Clostridium difficile. Report
> Dyax and Debiopharm have restructured their development agreement on DX-890 (Depelestat), a recombinant inhibitor of humanneutrophil elastase for pulmonary disorders. Release
> CuraGen has changed the terms of its collaboration with Bayer for a new diabetes therapy. Report
> Mylan Pharmaceuticals has entered into two agreements with Ortho-McNeil Pharmaceutical and Alza Corporation relating to oxybutynin chloride extended release tablets. Release
And Finally… Despite being dealt a major setback in its effort to break Pfizer's patent on Lipitor, Ranbaxy says it has no plans to back away from its aggressive strategy of challenging patents. Article